ID   MOLM/AZA-1
AC   CVCL_WI20
DR   Wikidata; Q95990499
RX   PubMed=28052028;
CC   Population: Japanese.
CC   Doubling time: 17 hours (PubMed=28052028).
CC   Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   NCIt; C3247; Myelodysplastic syndrome
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2119 ! MOLM-13
SX   Male
AG   20Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 29-06-23; Version: 9
//
RX   PubMed=28052028; DOI=10.18632/oncotarget.14342;
RA   Hur E.-H., Jung S.-H., Goo B.-K., Moon J., Choi Y., Choi D.R.,
RA   Chung Y.-J., Lee J.-H.;
RT   "Establishment and characterization of hypomethylating agent-resistant
RT   cell lines, MOLM/AZA-1 and MOLM/DEC-5.";
RL   Oncotarget 8:11748-11762(2017).
//